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Key points 
• Functional mitochondria are transferred in–vivo from BMSC to the leukemic 
blast. 
• AML derived NOX-2 drives transfer of mitochondria via the generation of 
superoxide. 
 
 
Abstract 
 
Improvements in the understanding of the metabolic cross-talk between cancer and 
its micro-environment is expected to lead to novel therapeutic approaches. Acute 
myeloid leukemia (AML) cells have increased mitochondria compared to non-
malignant CD34+ hematopoietic progenitor cells. Furthermore, contrary to the 
Warburg hypothesis, (AML) relies on oxidative phosphorylation to generate ATP. 
Here we report that in human AML NOX2 generates superoxide, which stimulates 
bone marrow stromal cells (BMSC) to AML blast transfer of mitochondria through 
AML derived tunnelling nanotubes. Moreover, inhibition of NOX2 was able to prevent 
mitochondrial transfer, dramatically increase AML apoptosis and increase NSG 
mouse survival. Conversely, mitochondrial transfer could only be stimulated from 
BMSC to non-malignant CD34+ cells in response to oxidative stress. However, 
NOX2 inhibition had no detectable effect on non-malignant CD34+ cell survival. 
Taken together we identify tumor-specific dependence on NOX2 driven 
mitochondrial transfer as a novel therapeutic strategy in AML. 
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Acute myeloid leukemia (AML) is an aggressive disease that originates in the bone 
marrow from malignant transformation of a myeloid progenitor cell. AML can occur at 
any age but primarily affects the elderly, with the average age at diagnosis of 72 
years and three quarters of patients diagnosed after the age of sixty 1.  Despite 
existing cytotoxic treatments directly targeting the leukemic cell two-thirds of younger 
adults and 90% of older adults will die of their disease 2. Moreover, current 
aggressive chemotherapy regimens are often poorly tolerated by the older less fit 
patients. Improved outcomes are expected to be achieved through novel therapies 
which are developed from an improved understanding of the biology of the disease.  
 
AML blasts cultured in vitro undergo high levels of apoptosis, however the tumor 
rapidly proliferates in vivo demonstrating that the tissue microenvironment plays a 
fundamental role in the development of AML disease 3,4. The bone marrow 
microenvironment consists of many cell types not directly involved in 
haematopoiesis. These include endothelial cells; osteoclasts; osteoblasts; 
adipocytes and fibroblasts 5, which are broadly classed as bone marrow stromal cells 
(BMSCs) and have previously been shown to support AML survival and contribute to 
chemotherapy resistance 6.  
 
In general cancer cells depend on aerobic glycolysis to generate ATP, as 
hypothesised by Warburg in 1956 7 and this is thought to be due to activation of 
oncogenes that promote glycolysis 8. However the metabolism of AML blasts differs 
from most other cancers in so much as AML is primarily dependent on mitochondrial 
oxidative phosphorylation for survival 9. It is also established that AML cells have 
higher mitochondria levels compared to non-malignant haematopoietic stem cells 
10,11
, which is entirely consistent with the observations that the tumor is dependent on 
a mitochondrial ATP production pathway. This proposes a key question; are the 
additional mitochondria in the AML blasts generated within the tumor cell or have 
they been acquired?  
 
For a long time mitochondria were thought to be retained in their somatic cell for their 
lifetime, however in 2004 the Gerdes lab showed that mitochondria can be 
transferred between cells 12. The main cell type in the bone marrow 
microenvironment, BMSC have been shown to donate their mitochondria to lung 
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epithelial cells preventing acute lung injury 13. This would suggest that BMSC have 
the capacity to donate their mitochondria within the bone marrow niche. In the 
present study we look to identify if and how BMSC transfer their mitochondria to AML 
blasts. Furthermore, we evaluate the mechanisms controlling the increase in 
mitochondria in AML blasts and finally whether blocking this process is specifically 
lethal to the tumor but not to the counterpart non-malignant hematopoietic progenitor 
cells in the bone marrow. 
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Methods 
Materials 
Anti-CD45-FITC, anti-CD33-APC, anti-CD90-FITC, anti-CD73-PE, anti-CD105-APC 
antibodies and CD34 microbeads were purchased from Miltenyi Biotec (Auburn, CA, 
USA). CellROX green, MitoTracker Green FM and Vybrant Dil stain were purchased 
from ThermoFisher (Waltham, MA, USA). Human Mitochondrial DNA (mtDNA) 
Monitoring Primer Set and the rLV.EF1.mCherry-mito-9 Lentivirus were purchased 
from Clontech Takara Bio Europe (Saint-Germain-en-Laye, France). Murine 
mitochondrial to nuclear DNA ratio kit was purchased from Detroit R&D (Detroit, MI, 
USA). All other reagents were obtained from Sigma-Aldrich (St Louis, MO, USA), 
unless otherwise indicated. 
 
Primary cell culture and differentiation 
Primary AML blasts were obtained from patient bone marrow following informed 
consent and under approval from the UK National Research Ethics Service 
(LRCEref07/H0310/146). Non-malignant CD34+ haematopoietic stem cells (HSC) 
were obtained from peripheral blood venesections from normal patients. AML cell 
isolation was carried out by density gradient centrifugation using Histopaque (Sigma-
Aldrich) and cell type was confirmed by flow cytometry as previously described 14. 
CD34+ HSC were isolated using density gradient centrifugation and CD34+ 
microbeads (Miltenyi Biotec). Bone marrow stromal cells (BMSC) were isolated by 
adherence to tissue culture plastic and were then expanded in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 20% foetal bovine serum (FBS) and 
supplemented with 1% penicillin-streptomycin (Hyclone, Life Sciences). BMSC 
markers were confirmed using flow cytometry for expression of CD90+, CD73+, 
CD105+ and CD45-. 
 
Flow cytometry 
For this study we used the CyFlow Cube 6 (Sysmex, Milton Keynes, UK). Cells were 
incubated for 5 minutes with the FCR receptor blocker (MIltenyi Biotec, Cat. 130-
059-901) and then stained with isotype controls or test antibodies (Miltenyi Biotec). 
Gates were set to the appropriate isotype control.  
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Mitochondrial Mass determination 
To assess mitochondrial DNA copy number we performed direct qRT-PCR of 
primary cells using Terra qPCR Direct Polymerase mix and Human Mitochondrial 
DNA (mtDNA) Monitoring Primer Set (Clontech Takara Bio Europe) according to 
manufactures protocols. 
 
MitoTracker based mitochondrial transfer assay 
Human primary BMSC were stained with 200nM MitoTracker Green FM for 1 hour. 
Primary AML blasts were also stained with 200nM MitoTracker Green FM for 30 
mins. Both cell types were washed three times in phosphate buffered saline (PBS) to 
remove the unbound probe. Stained AML blasts were added to stained BMSC at a 
5:1 ratio for 24 hours. Stained AML were also grown in mono-culture for 24 hours as 
a control. After incubation AML were removed from BMSC and MitoTracker 
fluorescence in these cells was analysed using the CyFlow Cube 6 flow cytomter 
(Sysmex, Milton Keynes). This assay was used to quantify mitochondrial transfer to 
determine the stimulus mechanism, the difference in MitoTracker fluorescence 
between AML blasts grown with and without BMSC provided a baseline 
mitochondrial transfer. A pharmacological screen was carried out, whereby 
numerous drugs and pathway inhibitors were added to the MitoTracker based co-
culture, glutathione, hydrogen peroxide and diphenyleneiodonium chloride (Sigma 
Aldrich) were used further with additional patient AML blasts. 
 
AML xenograft model 
All in-vivo studies were carried out following approvals from the UK home office and 
Animal Welfare and Ethics Board of the University of East Anglia. For this study the 
NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ (NSG) mice (The Jackson Laboratory, Bar 
Harbour, ME, USA) were housed under specific pathogen-free conditions in a 12/12-
hour light/dark cycle with food and water provided ad libitum in accordance with the 
Animal (Scientific Procedures) Act, 1986 (UK). 2x106 primary AML blasts were 
intravenously injected into non-irradiated 6-8 week old NSG mice. 2.5x105 OCI-
AML3-luc cells were injected, as per the primary blasts, for the NOX-2 KD xenograft. 
Mice injected with OCI-AML3-luc cells were monitored via in vivo bioluminescent 
imaging (Bruker, Coventry UK). At pre-defined humane end points mice were 
sacrificed (6-12 weeks post injection), bone marrow isolated and engraftment 
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determined using human CD33 and CD45 expression. Human AML blasts were 
purified from the heterogeneous bone marrow by MACS using CD45 microbeads. 
This purified human AML blast population was used for the PCR and agarose gel 
electrophoresis. Levels of mitochondria in the purified OCI-AML3-luc populations 
was achieved using MitoTracker Green FM staining and flow cytometry.   
 
Murine mitochondrial DNA detection 
Murine mitochondrial DNA detection was used to determine if inter-species 
mitochondrial transfer occurred from murine BMSC to human AML blasts. This 
method was used for both the in vitro culture and in vivo study. DNA from the purified 
human AML blasts was extracted using the GenElute mammalian DNA miniprep kit. 
8ng of DNA was added to the PCR reaction containing Sybr green and murine 
primers provided in the Detroit R&D kit. PCRs were amplified for 40 cycles (95°C/15 
seconds, 60°C/60 seconds) on a Roche 96-well LightCycler480. PCR products were 
run on a 1.25% agarose gel at 100V for 1 hour. Detection was performed by 
Chemdoc-It2 Imager (UVP) and analysed using ImageJ.  
 
Fluorescence and Confocal Microscopy 
Primary human BMSC were transduced with a rLV.EF1. mCherry-Mito-9 Lentivirus 
and were cultured with primary AML blasts for between 72 hours and 3 weeks. Live 
cell imaging was carried out in FluoroBrite DMEM media supplemented with 10% 
FBS (Hyclone, Life Sciences). Cytochalasin B (Sigma Aldrich) was added to the 
culture to analyse tunnelling nanotube formation (TNT). To visualise TNTs BMSC 
were stained with 100nM MitoTracker green FM and AML were stained with Vybrant 
Dil stain to visualise cell membranes. After co-culture cells were fixed with 4% 
paraformaldehyde and imaged. Fluorescence and bright field images were acquired 
on Zeiss Axio Vert.A1 microscope with 20X and 40X air objectives (Carl Zeiss) 
confocal images were acquired on Zeiss LSM 800 Axio Observer.Z1 confocal 
microscope with 40X and 63X water objectives (Carl Zeiss). 
 
2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) and CellROX assays 
BMSC after a 24h co-culture with primary AML blasts were stained with 20µM 
H2DCFDA (Sigma Aldrich) for 30 mins at 37°C in FluoroBrite DMEM media 
supplemented with 10% FBS, BMSC grown alone were also stained. After incubation 
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cell were washed in PBS before flow cytometry analysis of the H2DCFDA 
fluorescence. Live fluorescence microscopy cell imaging was also used to visualise 
BMSC ROS. AML cells were not removed from the BMSC, H2O2 and NAC were 
also used with the same concentrations as the MitoTracker pre-stain assay. 
 
For the CellROX assay BMSC were cultured with primary AML blasts for 24 hours or 
stimulated with H2O2 and then stained with 10µM CellROX green reagent 
(ThermoFisher Waltham, MA, USA) for 30 minutes. After incubation the cells were 
washed with PBS and analysed using confocal microscopy. 
 
Lentiviral transduction 
NOX-2 shRNA glycerol stock was purchased from Sigma Aldrich 
(TRCN0000064588). Lentivirus particles generated using this construct were 
produced as previously described 15. Lentiviral stocks were concentrated using 
Amicon® Ultra centrifugal filters and titres were determined using Lenti-X™ qRT-
PCR titration kit (CloneTech). Primary AML blasts were plated at a density of 
5x104/well in a 24 well plate and infected with the NOX-2 lentivirus at MOI 30. NOX-2 
knockdown was confirmed using qRT-PCR.  
 
Real-time polymerase chain reaction 
Reverse transcription was performed using an RNA polymerase chain reaction 
(PCR) core-kit (Applied Biosystems). Relative quantitative real-time (qRT)-PCR used 
SYB-green technology (Roche) on generated complementary DNA. After pre-
amplification (95°C/60 seconds), PCRs were amplified for 45 cycles (95°C/15 
seconds, 60°C/10 seconds, 72°C/10 seconds) on a Roche 384-well LightCycler480. 
Messenger RNA (mRNA) expression was normalized against glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). 
 
Apoptosis 
Apoptosis of AML blasts and non-malignant CD34+ HSC was measured using 
PI/AnnexinV (eBiosciences) after co-culture with AML blasts and was quantified 
using flow cytometry. 
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Amplex Red Superoxide Assay 
The amplex red hydrogen peroxide/peroxidase assay kit was used to determine 
superoxide production was control KD vs NOX-2 KD AML blasts. 1x105 cells were 
plated in a 96 well plate for 48 hours in FluoroBrite DMEM media supplemented with 
10% FBS. The assay was carried out as per manufacturer’s protocol with a H2O2 
standard curve allowing superoxide quantification. 
 
Mitochondrial Respiration 
Mitochondrial respiration in AML blasts was assessed using the Seahorse XFp 
Analyzer, as previously described 16, and the Seahorse XF Mito stress test kit 
(Agilent Seahorse Bioscience) according to manufacturer’s specifications. Briefly, 
AML blasts were cultured with or without BMSC and then removed from co-culture 
and plated in poly-D-lysine (Sigma) coated assay wells at a density of 2x105 per well 
in base media containing 2.5mM glucose, 0.5mM carnitine and 5mM HEPES. 
Oligomycin (2µM), FCCP (0.25µM) and Rotenone (0.5µM) were added into the 
injection ports. The experimental template was designed using Wave software for 
desktop from Seahorse Bioscience. ATP production was monitored by the CellTitre-
Glo assay (Promega). 
 
Statistical analysis 
We used the Mann-Whitney U test, Wilcoxon matched pairs test and paired t test to 
compare results between groups. The Mantel-Cox test was used to analyse Kaplan-
Meier survival curves. Results with P < 0.05 (denoted by *), P < 0.01 (denoted by **) 
P < 0.001 (denoted by ***) were considered statistically significant. Results represent 
the mean ± Standard Deviation of 4 independent experiments. We generated 
statistics with Graphpad Prism 5 software (Graphpad, San Diego, CA, USA). 
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Results 
BMSC donate their mitochondria to leukemic blasts.  
As previously reported human AML blasts have an increased mitochondrial mass 
compared to non-malignant CD34+ progenitor cells 10,11 (Figure 1A). To determine if 
BMSC support the increase of mitochondria in AML we examined mitochondrial 
content after in-vitro co-culture. Figure 1B shows that AML increase their 
mitochondrial mass after co-culture with BMSC. Next we used 3 different methods to 
show that BMSC transfer their mitochondria to primary human AML.  
 
First, we assessed mitochondrial transfer between our patient derived BMSC and 
primary AML blasts by infecting BMSC with a rLV.EF1.mCherry-Mito-9 Lentivirus for 
stable production of mitochondria incorporated mCherry tagged protein. Using this 
we observed that primary AML blasts, after co-culture with these BMSC, acquired 
the mCherry fluorescence (Figure 1C and 1D). This demonstrates that mitochondria 
from the BMSC with the mCherry tag move to the AML blasts. 
 
Second, we used MitoTracker Green FM stain to quantify mitochondria in AML after 
co-culture with BMSC. We incubated both BMSC and AML with MitoTracker Green 
FM stain for 1h. The cells were washed twice in PBS and incubated for 4 h. The cells 
were then co-cultured for 24 h and then measured for MitoTracker fluorescence 
using flow cytometry. Figure 1E shows that AML in cultured with BMSC had 
significantly more mitochondria than AML cells cultured alone. This was also the 
case for the OCI-AML3 cell line (Supplementary Figure 1A). To begin to address 
whether this is a tumor specific phenomenon we repeated the experiment using non-
malignant CD34+ cells in the BMSC assay and showed no significant increase in 
MitoTracker fluorescence in the hematopoietic progenitor cells (Figure 1F).       
 
Third, we used an in-vivo xenograft model in which human primary AML were 
transplanted into NSG mice. Following tumor engraftment we determined if mouse 
mitochondrial DNA (mtDNA) could be detected in the human leukemia cells after 
extraction from NSG bone marrow. Four individual patient AML samples were 
transplanted into 8 NSG mice and following engraftment at between 6 and 12 weeks 
human AML blasts were isolated via human CD45 sorting (Figure 2A). Primary AML 
blasts reliably engrafted into NSG mice, verified by human CD33 and CD45 
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expression confirming human AML blast identity (Figure 2B) and Figure 2C shows 
that the human CD45 sorted cells were a pure population. Next we wanted to 
determine if the engrafted AML and subsequent CD45 purified human blasts had 
acquired mouse mitochondria. To do this we performed a PCR analysing mouse 
mitochondrial DNA and mouse genomic DNA.  Figure 2D shows that AML blasts 
isolated from engrafted NSG mice contained mouse mitochondrial DNA but not 
mouse genomic DNA, this was also the case for the OCI-AML3 cell line (Figure 2E). 
Taken together these 3 methods show that mitochondria are transferred from BMSC 
to leukemic blasts both in vitro and in vivo. 
 
Mitochondria transfer occurs via leukemia derived tunnelling nanotubule (TNT) 
A constant observation from live cell imaging was that AML blasts that acquire the 
mCherry fluorescence are in direct contact with the BMSC, this led us to investigate 
whether a cell-cell interaction is the way mitochondria move between the two cell 
types (figure 1C). We first hypothesised that tunnelling nanotubes (TNT) facilitate 
mitochondrial transfer from BMSC to AML blasts. To inhibit TNT formation we added 
cytochalasin B to our mCherry-Mito-9 BMSC-AML co-culture experiment. Figure 3A 
and 3B show that there is a significant reduction in the percentage of AML blasts that 
acquire the mCherry fluorescence after cytochalasin B treatment. This suggests that 
mitochondria from the BMSC are transferred to the AML blast via TNTs.  
 
TNTs are functionally dynamic, so in order to visualise the transfer of mitochondria 
we used a fixed cell based imaging. To do this we stained AML blasts with the 
Vybrant lipid stain (red) and the mitochondria in BMSC cells with MitoTracker Green 
FM stain and then cultured the cells together for 24 hours. Following co-culture the 
cells were fixed and TNT formation was detected using confocal microscopy. In 
Figure 3C we observed green mitochondria from the BMSC in the red TNT projecting 
from the AML blasts. 
 
ROS regulates the transfer of mitochondria from BMSC to leukemia blasts 
It is not known what stimulates mitochondrial transfer in AML or any cancer. 
Moreover, determination of the controlling stimulus is essential if this biological 
phenomenon is to be exploited therapeutically in the future.  
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To identify the mechanism of mitochondrial transfer in AML we used a 
pharmacological screen in which the MitoTracker experiment described in Figure 1 
was employed as a screening tool. Figure 4A shows that N-acetyl cysteine (NAC), 
glutathione (GSH) and diphenyleneiodonium (DPI) inhibit mitochondrial transfer. In 
contrast we observe that hydrogen peroxide (H2O2), daunorubicin and cobalt chloride 
further enhance mitochondrial transfer from BMSC to AML blasts. In our baseline 
experimental conditions mitochondria did not transfer from BMSC to non-malignant 
CD34+ cells (Figure 1F). However, the addition of H2O2 to the co-culture of non-
malignant CD34+ cells and BMSC co-cultures was able to induce mitochondrial 
transfer to the CD34+ cells. Next we wanted to determine if AML blasts are 
responsible for an increase in ROS levels in BMSC. To do this we analysed BMSC 
ROS when cultured with AML using two assays CellROX and 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA) assay.  Figure 4E, F and G shows 
that culture with AML blasts causes increased ROS levels and oxidative stress in the 
BMSC. Figure 4H shows that non-malignant CD34+ cells do not increase ROS levels 
in BMSC. Taken together these results, show that AML induced ROS stimulate 
mitochondrial transfer from BMSC.   
 
AML derived NOX-2 drives mitochondrial transfer 
We observed that diphenyleneiodonium (DPI) was able to inhibit mitochondrial 
transfer in our assays (Figure 5A, Supplementary Figure 1B). As DPI inhibits NOX-2, 
and NOX-2-derived ROS plays a critical role in mobilization and homing of non-
malignant hematpoietic stem cells 17, we next asked whether NOX-2 derived 
superoxide produced by the AML was responsible for mitochondrial transfer. We 
knocked down NOX-2 using a lentiviral transduction (Figure 5B) in 4 human AML 
patient cell samples and the OCI-AML3 cell line. Then we analysed mitochondrial 
transfer to AML following NOX-2 or control shRNA knockdown. Figure 5C shows a 
significant reduction in mitochondrial transfer in the NOX-2 KD AML cells compared 
to control KD blasts, also consistent with the OCI-AML3 cell line (Supplementary 
Figure 1C). To confirm that superoxide was reduced in the NOX-2 KD cells we 
analysed superoxide using the AmplexRED assay. Figure 5D shows that NOX-2 KD 
cells have significantly reduced superoxide. Next we tested if AML with NOX-2 KD 
could increase ROS in BMSC. Figure 5E shows that NOX-2 KD AML cells had a 
reduced capacity to stimulate ROS production in the BMSC compared to control KD 
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blasts. Finally, we tested if DPI could reduce survival of AML in culture with BMSC. 
Figure 5F shows that AML blast survival on BMSC is inhibited by the addition of DPI. 
Moreover, DPI had little or no effect on the viability of non-malignant CD34+ cells 
grown in co-culture with BMSC (Figure 5G). Taken together in leukemic blasts NOX2 
derived superoxide stimulates ROS generation in BMSC which results in 
mitochondrial transfer from the stroma to the tumor.   
 
Mitochondria acquired by the AML blast are functionally active and contribute 
to the metabolic capacity 
We next explored the function of mitochondrial transfer in relation to mitochondrial 
respiration. We found that after co-culture with BMSC AML blasts have increased 
basal and maximum mitochondrial respiration compared control cells (Figures 6A 
and 6B). In addition, the ATP production capacity of AML blasts in co-culture with 
BMSC was increased compared to control cells (Figure 6C). This shows that 
mitochondria in AML after co-culture with BMSC are functional and contribute to 
energy requirements of the rapidly proliferating cancer cell. To determine if the 
mitochondria transferred are responsible for this increased respiration, we analysed 
the mitochondrial respiration in the control and NOX-2 knockdown primary AML 
blasts in co-culture with BMSC. We found that knockdown blasts had significantly 
reduced basal and maximum mitochondrial respiration (Figure 6D), showing that 
mitochondrial transfer has to occur in order for AML to have increased mitochondrial 
output when cultured with BMSC.  
 
NOX-2 is crucial for the development of AML in an in vivo xenograft model 
To analyse in the impact of NOX-2 on mitochondrial transfer and disease 
progression, we engrafted control KD and NOX-2 KD OCI-AML3-luc cells into NSG 
mice. Mice were imaged using bioluminescence at weekly intervals. These images 
revealed that there is reduced AML disease progression and engraftment in the bone 
marrow with NOX-2 KD cells compared to the control KD cells (Figure 7A). Disease 
progression was monitored until humane end point, the survival of the NOX-2 KD 
mice was significantly increased compared to the control KD mice (Figure 7B). OCI-
AML3-luc reliably engrafted into NSG mice, verified by human CD45 expression 
confirming human AML blast identity (Figure 7C). Mitochondrial levels were analysed 
in the two cell populations pre and post engraftment into the NSG mice, using 
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MitoTracker Green FM. There was no difference in the mitochondrial levels between 
the control and NOX-2 KD pre-engraftment (Figure 7D). However in the purified OCI-
AML3-luc cells post engraftment, the control KD cells had significantly increased 
mitochondrial levels compared to NOX-2 KD cells (Figure 7E). Taken together these 
results show that there is reduced mitochondrial transfer in vivo to NOX-2 KD cells 
compared to control KD cells. This reduces the engraftment and disease progression 
in these cells and enhances survival.  
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Discussion 
In this study we report that BMSC within the protective microenvironment of AML 
transfer their mitochondria to AML blasts. Furthermore, we show that mitochondria 
are transferred via AML-derived TNTs. We identified that AML derived ROS drives 
mitochondrial transfer from the BMSC to the AML. Specifically, NOX-2 derived 
superoxide generated from the AML causes mitochondrial transfer, shown through in 
vitro and in vivo studies. We were able to reduce mitochondrial transfer using both 
lentiviral knockdown and pharmacological inhibition of NOX2. Overall our results 
provide a first in cancer mitochondrial transfer mechanism, whereby the cancer cell 
drives transfer through increasing oxidative stress in the non-malignant donor cell.  
 
Mitochondrial transfer is known to occur in other cancers such as breast 18, lung 19 
and melanoma 20.  Our work shows in patient derived AML blast and BMSC 
samples, using three in vitro methods and an in vivo model that mitochondrial 
transfer was also observed between the BMSC and the AML blast. The mitochondria 
that move to the AML are also functionally active, highlighting that the AML blast is 
using this biological phenomenon to its metabolic advantage. As Mitochondrial 
transfer has been shown to occur via TNTs in some cancers 18,21,22, whereas in other 
disease contexts it has been shown to be via connexin-43 GAP junctions 13. A 
constant observation was that AML blasts which acquired mitochondria were in 
contact with BMSC, therefore we first analysed whether the mitochondria could be 
moving via TNTs in our AML cancer setting. Through the addition of cytochalasin B 
to the co-culture and capturing the dynamic interactions through confocal 
microscopy, we report that mitochondria move from BMSC to AML blasts 
predominantly through TNTs. In previous literature presenting mitochondrial transfer 
in AML it was suggested that mitochondria moved between cells via endocytosis 23. 
Our results do not disprove this idea and it is possible a combination of the two 
mechanisms (or possibly more) contribute to the total mitochondria that are acquired 
by the AML blast. The TNT mechanism is however necessary for AML survival.  
 
Through the pharmacological screen we highlighted that inducing ROS increased 
mitochondrial transfer, whereas inhibiting ROS reduced transfer. Additionally, we 
found that AML blasts increase oxidative stress in the BMSC. Chronic oxidative 
stress has been shown to aid tumour survival 24, metastasis 25 and proliferation 26. It 
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is also known that there are high levels of oxidative stress in AML 27 and that in AML 
disease relapse there are increased markers of oxidative stress 28. As we have 
shown oxidative stress drives mitochondrial transfer, this biological phenomenon 
may be the underlying reason why oxidative stress promotes AML proliferation and 
relapse. Interestingly using H2O2 we could stimulate mitochondrial transfer to non-
malignant CD34+ cells, which do not otherwise acquire mitochondria under baseline 
conditions, AML acts in a ‘parasitic’ way by generating the hypoxic conditions in the 
bone marrow necessary for mitochondrial transfer from stromal cells. 
 
We show that specifically NOX-2 generated superoxide derived from the AML blasts 
drives the observed mitochondrial transfer, which provides a molecular target for the 
process. NOX-2 has an established role in immune defence whereby superoxide 
produced by NOX-2 on phagocytic myeloid cells destroys pathogens 29. Through DPI 
drug inhibition of NOX-2 we show that in co-culture with BMSC, the cell viability of 
AML blasts is significantly reduced highlighting the significance of NOX-2 in AML 
disease. NOX-2 knockdown blasts have reduced mitochondrial respiration compared 
to control knockdown cells, therefore the metabolic requirements of the blasts may 
not be met resulting in the observed cell death. Inhibition of NOX-2 in vivo 
highlighted that NOX-2 and the resultant mitochondrial transfer is essential for AML 
disease progression, whereby NSG mice administered with NOX-2 KD AML out 
survived their control counterparts. Interestingly in vitro, the cell viability of non-
malignant CD34+ cells is unaffected upon the addition of DPI to the co-culture. It has 
been previously described that AML blasts produce a greater quantity of NOX-2 
derived superoxide than non-malignant CD34+ cells 30. This knowledge combined 
with the fact non-malignant CD34+ cells do not acquire mitochondria from BMSC 
and do not stimulate oxidative stress in the BMSC opens up a novel therapeutic 
window. Mitochondrial transfer from BMSC could be targeted therapeutically through 
NOX-2 inhibition without any detrimental effects to the normal haematopoietic 
system. 
 
Overall we report a first in cancer mitochondrial transfer mechanism whereby NOX-2 
derived oxidative stress drives transfer from non-malignant BMSC to AML blasts. 
Moreover, we show that this mitochondrial transfer is fundamentally a part of the 
malignant AML phenotype. Accordingly, these results may have the ability to be 
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translated into other malignancies where mitochondrial transfer has previously been 
observed but, where the specific mechanism have yet to be elucidated. Finally, our 
results identify a novel therapeutic opportunity to be developed and explored for the 
treatment of AML. 
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Figure Legends 
Figure 1. BMSC donate their mitochondria to leukemic blasts. (A) Mitochondrial 
DNA copy number was assessed in primary non-malignant CD34+ cells (n=7) and 
AML blasts (n=9) (P=0.0164). (B) Mitochondrial DNA copy number was assessed in 
primary AML blasts (n=6) in mono-culture vs co-culture with BMSC for 72 hours and 
1 week (P=0.0022). (C) BMSC were transduced with a rLV.EF1. mCherry-Mito-9 
Lentivirus. AML blasts were cultured on mCherry-Mito-9 positive BMSC and were 
analysed by live cell imaging after a 1 week culture. Bright field, mCherry and 
merged channels are shown. (D) Live cell imaging was repeated with 5 primary AML 
patient samples, the percentage of mCherry positive AML blasts is presented. (E and 
F) Primary AML blasts (n=11) or non-malignant CD34+ cells (n=7) were pre-stained 
with 200nM MitoTracker Green FM for 24 hours on BMSC stained with MitoTracker 
Green FM, MitoTracker fluorescence was analysed in the AML blasts (P=0.001) and 
non-malignant CD34+ cells (p<0.05) by flow cytometry.  
 
Figure 2. Human AML acquire mouse mitochondria in NSG xenograft model. 
(A) schematic representation of PDX model used for these experiments. (B) 2x106 
primary AML cells (4 individual patient AML) were I.V. injected into NSG mice. 
Engraftment was measured using human CD33 and human CD45. In the dot plot 
each AML engraftment into NSG mice is shown for bone marrow and spleen. (C) 
Engrafted AML were purified from the mouse BM using human CD45 cell sorting.  
Shown in the flow figure are the characteristics of AML#12 engraftment into BM and 
spleen. (D) Total DNA was extracted from the purified AML and analysed by PCR for 
murine and human specific mitochondrial and genomic DNA. PCR products were 
visualised by agarose gel electrophoresis. (E) OCI-AML3 cells engrafted into NSG 
mice were also analysed by PCR and agarose gel electrophoresis. 
 
Figure 3. Mitochondria transfer to leukemic blasts occurs via TNT. (A) BMSC 
were transduced with a rLV.EF1. mCherry-Mito-9 Lentivirus. AML blasts were 
cultured on mCherry-Mito-9 positive BMSC and were analysed by live cell imaging. 
With and without cytochalasin B. (B) Multiple primary AML blasts were cultured on 
rLV.EF1. mCherry-Mito-9 Lentivirus transduced BMSC with and without cytochalasin 
B the percentage of mCherry positive AML is shown. (C) AML blasts were stained 
with Vybrant Dil for 1 h and washed 3 times in PBS. BMSC were stained with 
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MitoTracker green FM for 1 h and washed 3 times in PBS. AML blasts and BMSC 
were then cocultured for 24 hours before fixation using paraformaldehyde. Cells 
were visualised by confocal microscopy.  
 
Figure 4. ROS regulate the transfer of mitochondria from BMSC to AML blast. 
(A) Primary AML and BMSC were pre-stained with MitoTracker green FM for 1h and 
then cultured together before 24 h drug treatment. Flow cytometry was used to 
detect MitoTracker green FM in the AML blast. (B) Primary AML (n=7) and BMSC 
were pre-stained with MitoTracker green FM for 1h and then cultured together before 
24 h NAC (5mM) and GSH (5Mm) treatment. Flow cytometry was used to detect 
MitoTracker green FM in the AML blast. (C)  Primary AML (n=10) and BMSC were 
pre-stained with MitoTracker green FM for 1h and then cultured together before 24 h 
H2O2 (50µM).  Flow cytometry was used to detect MitoTracker green FM in the AML 
blast. (D)  non-malignant CD34+ cells (n=7) and BMSC were pre-stained with 
MitoTracker green FM for 1h and then cultured together before 24 h H2O2 (50µM).  
Flow cytometry was used to detect MitoTracker green FM in the malignant CD34+ 
cells. (E)  BMSC cultured alone and in co-culture with AML or treated with H2O2 
(50µM) AML were removed and BMSC were stained for ROS using CellROX. BMSC 
were visualised for ROS using fluorescence microscopy. (F)  BMSC cultured alone 
and in co-culture with AML or treated with H2O2 (50µM) AML were removed and 
BMSC were stained for ROS using H2DCFDA (10µM).  BMSC were visualised for 
ROS using fluorescence microscopy or flow cytometry (G) BMSC cultured alone and 
in co-culture with non-malignant CD34+ cells or treated with H2O2 (50µM) AML were 
removed and BMSC were stained for ROS using H2DCFDA (10µM).  BMSC were 
visualised for ROS flow cytometry. 
 
Figure 5. AML derived NOX-2 drives mitochondrial transfer. (A) Primary AML 
(n=11) and BMSC were pre-stained with MitoTracker green FM for 1h and then 
cultured together before 24 h treatment with DPI (1µM).  (B)  4 AML patient samples 
were transduced with a lentivirus targeted to NOX-2 or control for 72 h. NOX-2 
mRNA levels were analysed by real-time PCR and normalised to GAPDH. (C, D, E 
and F) 4 AML patient samples were transduced with a lentivirus targeted to NOX-2 
or control for 72 h. KD AML cells and BMSC were pre-stained with MitoTracker 
green FM for 1h and then cultured together before 24 h. MitoTracker was detected 
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by was detected by flow cytometry.  (D) Superoxide production was detected in 
NOX-2 and control KD AML cells by AmplexRED assay. (E) BMSC were cultured 
with control KD AML or NOX-2 KD AML. BMSC were stained for ROS using 
H2DCFDA (10µM) and visualised for ROS using flow cytometry. (F) Primary AML or 
(G) non-malignant CD34+ were cultured with BMSC and treated with DPI (1µM) for 
72 h. AML blasts or non-malignant CD34+ cells were stained with Annexin V and 
analyses by flow cytometry.  
 
Figure 6. Mitochondria acquired by the AML blast are functionally active and 
contribute to the metabolic capacity. (A) Primary AML blasts were grown with and 
without BMSC for 72 hours and then analysed independently using the Seahorse 
XFp Analyser with the Mito Stress Test Kit. Data represented as mean ± standard 
deviation. Sequential injections of Oligomycin (O), FCCP (F) and Rotenone (R) were 
used to obtain respiration dynamics presented in (B). (C) Primary AML blasts were 
grown with and without BMSC and after 72 hours the ATP production capacity was 
analysed by CellTitre-Glo, with cells numbers normalised. (D) BMSC were cultured 
with control KD AML or NOX-2 KD AML for 72 hours. The blasts were then analysed 
using the Seahorse Extracellular Flux Analyser, basal and maximum mitochondrial 
respiration is presented. 
 
Figure 7. NOX-2 is crucial for the development of AML in an in vivo xenograft 
model. (A) Mice were imaged using bioluminescence weekly to monitor engraftment 
and disease progression in the animals administered with control and NOX-2 KD 
cells. (B) The survival of NSG mice administered with either control KD or NOX-2 KD 
OCI-AML3-luc cells. (C) Engraftment of AML in bone marrow harvested post human 
end point was analysed by flow cytometry for human CD45 expression. (D) 
Mitochondrial levels were analysed in the OCI-AML3-luc pre engraftment by staining 
for 15 mins in 200mM MitoTracker Green FM. (E) Mitochondrial levels in the purified 
OCI-AML3-luc population were also analysed as in D. 
 
 







